Skip to main content

Vyant Bio Stock Forecast, Price & News

+0.43 (+14.93 %)
(As of 05/14/2021 01:27 PM ET)
Today's Range
50-Day Range
52-Week Range
Volume12,820 shs
Average Volume1.96 million shs
Market Capitalization$36.43 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive VYNT News and Ratings via Email

Sign-up to receive the latest news and ratings for Vyant Bio and its competitors with MarketBeat's FREE daily newsletter.

About Vyant Bio

Vyant Bio, Inc. operates as a biotechnology drug discovery company. The company, through its subsidiary, StemoniX, develops and manufactures at-scale human induced pluripotent stem (iPS) cell-derived neural and cardiac screening platforms for drug discovery and development. StemoniX, through collaborations with drug discovery organizations, tests compounds in-house, creates cell-based disease models, and operationalizes custom human iPSC-derived disease models for high-throughput screening. The company, through its subsidiary, vivoPharm, offers proprietary preclinical test systems supporting clinical diagnostic offerings at early stages by the pharmaceutical industry, biotechnology companies, and academic research centers. vivoPharm specializes in conducting studies to guide drug development, starting from compound libraries and ending with a set of in vitro and in vivo data and reports, as needed for investigational new drug filings. The company is based in Cherry Hill, New Jersey.


Vyant Bio (VYNT) to Release Quarterly Earnings on Tuesday
Vyant Bio (VYNT) to Release Quarterly Earnings on Tuesday
May 14, 2021 |
Vyant Bio (NASDAQ:VYNT) Stock Price Down 4.8%
Vyant Bio (NASDAQ:VYNT) Stock Price Down 4.8%
May 1, 2021 |
Vyant Bio Inc.
Vyant Bio Inc.
April 30, 2021 |
Vyant Bio Inc
Vyant Bio Inc
April 28, 2021 |
VYNT.OQ - Vyant Bio Inc Profile | Reuters
VYNT.OQ - Vyant Bio Inc Profile | Reuters
April 28, 2021 |
Cancer Genetics and StemoniX Announce Merger Closing
Cancer Genetics and StemoniX Announce Merger Closing
March 31, 2021 |
See More Headlines

Industry, Sector and Symbol

Industry Biotechnology
Current SymbolNASDAQ:VYNT
Phone201 479 1357
Year FoundedN/A

Sales & Book Value

Annual SalesN/A





Market Cap$36.43 million
Next Earnings Date5/18/2021 (Confirmed)
OptionableNot Optionable


Overall MarketRank

0.00 out of 5 stars

Medical Sector

2000th out of 2,039 stocks

Biotechnology Industry

144th out of 157 stocks

Analyst Opinion: 0.0Community Rank: 0.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Vyant Bio (NASDAQ:VYNT) Frequently Asked Questions

What stocks does MarketBeat like better than Vyant Bio?

Wall Street analysts have given Vyant Bio a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Vyant Bio wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Vyant Bio's next earnings date?

Vyant Bio is scheduled to release its next quarterly earnings announcement on Tuesday, May 18th 2021.
View our earnings forecast for Vyant Bio

How were Vyant Bio's earnings last quarter?

Vyant Bio, Inc. (NASDAQ:VYNT) posted its earnings results on Tuesday, April, 16th. The company reported ($0.14) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.16) by $0.02. The business had revenue of $6.80 million for the quarter.
View Vyant Bio's earnings history

How has Vyant Bio's stock been impacted by COVID-19?

Vyant Bio's stock was trading at $3.59 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, VYNT shares have decreased by 8.9% and is now trading at $3.27.
View which stocks have been most impacted by COVID-19

Who are Vyant Bio's key executives?

Vyant Bio's management team includes the following people:
  • Mr. Andrew D.C. LaFrence CPA, CPA, CFO & COO (Age 58, Pay $106.07k)
  • Mr. Yung-Ping Yeh M.B.A., M.S., P.M.P., Chief Innovation Officer & Director
  • Dr. Robert J. Petcavich, Chief Science Advisor & Director (Age 67, Pay $212.48k)
  • Mr. John A. Roberts M.B.A., MBA, Pres, CEO & Director (Age 62)
  • Dr. Ralf Brandt, Pres of Discovery & Early Devel. Services (Age 53)
  • Dr. Barb Jones Ph.D., Sr. VP of External & Regulatory Affairs

Who are some of Vyant Bio's key competitors?

What is Vyant Bio's stock symbol?

Vyant Bio trades on the NASDAQ under the ticker symbol "VYNT."

Who are Vyant Bio's major shareholders?

Vyant Bio's stock is owned by many different retail and institutional investors. Top institutional shareholders include Renaissance Technologies LLC (1.64%), BlackRock Inc. (1.50%), Geode Capital Management LLC (0.53%), GWM Advisors LLC (0.51%), Northern Trust Corp (0.18%) and Citigroup Inc. (0.09%).
View institutional ownership trends for Vyant Bio

Which major investors are buying Vyant Bio stock?

VYNT stock was purchased by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, BlackRock Inc., Geode Capital Management LLC, GWM Advisors LLC, Northern Trust Corp, and Citigroup Inc..
View insider buying and selling activity for Vyant Bio
or or view top insider-buying stocks.

How do I buy shares of Vyant Bio?

Shares of VYNT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Vyant Bio's stock price today?

One share of VYNT stock can currently be purchased for approximately $3.27.

How much money does Vyant Bio make?

Vyant Bio has a market capitalization of $35.99 million.

How many employees does Vyant Bio have?

Vyant Bio employs 29 workers across the globe.

What is Vyant Bio's official website?

The official website for Vyant Bio is

How can I contact Vyant Bio?

The company can be reached via phone at 201 479 1357.

This page was last updated on 5/14/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.